The histopathology report is the final product of the diagnostic workflow. It must communicate findings clearly, completely, and in a language understood by surgeons, oncologists, and other clinicians. Standardized reporting — particularly for cancer specimens — ensures all critical prognostic and predictive elements are documented.
Components of the Histopathology Report
Every report includes patient identifiers (name, date of birth, medical record number), specimen details (type, site, laterality, accession number), clinical history, and the requesting physician. The gross description documents specimen dimensions, weight, color, consistency, and any abnormalities seen with the naked eye — inked margins, sectioned surfaces, visible tumor. The microscopic description describes the histological findings: architecture, cytology, mitotic activity, stromal reaction, necrosis, vascular invasion, and margin status. The diagnosis (conclusion) states the pathologic entity using standardized nomenclature (SNOMED, ICD-O coding). Comment sections address specific clinical questions, differential diagnoses resolved, and recommendations for ancillary testing.
Synoptic Reporting
For cancer specimens, synoptic (checklist-based) reporting is now mandatory in many countries. The synoptic format ensures every essential element is recorded: tumor type, histological grade, tumor size, depth of invasion, margin status (distance and location), lymphovascular invasion, lymph node status (number examined, number positive, size of deposits), and pathological stage. Synoptic reports improve completeness rates from approximately 70% to over 95% compared to narrative-only reports. Templates are maintained by organizations such as the College of American Pathologists (CAP) and the Royal College of Pathologists (RCPath).
Histological Grading
Grading assesses the degree of differentiation of a tumor — how closely it resembles the normal tissue of origin. Well-differentiated tumors (low grade) retain architectural and cytological features of the parent tissue; poorly differentiated tumors (high grade) show minimal resemblance. Different grading systems exist for different tumor types. For breast cancer, the Nottingham (Elston-Ellis) grading system evaluates three components: tubule formation (1-3), nuclear pleomorphism (1-3), and mitotic count (1-3), summed to a total score of 3-9 and grouped into grades 1 (well-differentiated, score 3-5), 2 (moderately differentiated, 6-7), and 3 (poorly differentiated, 8-9). For prostate cancer, the Gleason grading system assigns primary and secondary patterns (each 1-5) summed to a Gleason score (2-10), now reported as Grade Groups (1-5). For IHC-based grading, Ki-67 proliferation index is increasingly used as a continuous variable.
Pathological Staging
Staging describes the anatomical extent of disease. The TNM staging system (AJCC/UICC) classifies primary tumor (T0-T4), regional lymph node involvement (N0-N3), and distant metastasis (M0-M1). Pathological stage (pTNM) is determined from the resected specimen and carries greater prognostic weight than clinical stage. Stage grouping (I-IV) combines TNM categories into clinically meaningful prognostic groups.
Margin Assessment
Surgical margins are reported as negative (uninvolved) when no tumor cells are present at the inked surface, or positive (involved) when tumor extends to the margin. The distance from tumor to the nearest margin is measured microscopically. Margin status is the strongest predictor of local recurrence in many cancers (breast, prostate, colorectal). Frozen section is commonly used for intra-operative margin assessment.
Ancillary Studies and Integrated Reporting
Modern reports integrate results from IHC, molecular testing, and cytogenetics. For example, a lung cancer report may include PD-L1 IHC tumor proportion score, EGFR and ALK mutation status, and PD-L1 expression level. Integrated reporting brings all actionable findings into a single document.
